双重血浆分子吸附系统治疗肝衰竭患者发生血管迷走神经反应相关因素分析及其处理对策研究*

doi:10.3969/j.issn.1672-5069.2022.06.018

实用肝脏病杂志 ›› 2022, Vol. 25 ›› Issue (6): 828-831.doi: 10.3969/j.issn.1672-5069.2022.06.018

双重血浆分子吸附系统治疗肝衰竭患者发生血管迷走神经反应相关因素分析及其处理对策研究^*

贺锦帆, 姚佳, 赵强, 王娟, 白津佳, 赵凝慧

030032 太原市山西医科大学第三医院(山西白求恩医院)消化内科

收稿日期:2022-07-05 出版日期:2022-11-10 发布日期:2022-11-22
通讯作者: 赵凝慧,E-mail:zhaoninghuihui@163.com
作者简介:贺锦帆,男,25岁,硕士研究生。E-mail:hejinfan115@qq.com
基金资助:
^*北京肝胆相照公益基金会资助项目(编号:RGGJJ-2021-033);山西省医学重点科研项目(编号:2021XM42);山西省重点研发计划项目(编号:201903D321125)

Vasovagal reaction in patients with liver failure during double plasma molecular adsorption system treatment

He Jinfan, Yao Jia, Zhao Qiang, et al.

Department of Gastroenterology, Bethune Hospital, Affiliated to Shanxi Medical University, Taiyuan 030032,China

Received:2022-07-05 Online:2022-11-10 Published:2022-11-22

摘要/Abstract

摘要： 目的探讨影响双重血浆分子吸附系统(DPMAS)治疗肝衰竭(LF)患者发生血管迷走神经反应(VVR)的相关因素和处理对策。方法 2021年1月～2022年3月山西白求恩医院消化内科诊治的LF患者82例和LF前期患者17例,均接受DPMAS治疗。VVR诊断依据患者在仰卧位时出现心动过缓(HR＜60次/分)和低收缩压(SBP＜100 mmHg),并伴有恶心、出汗、腹部不适、视力模糊、胸闷、排便、头晕、晕厥等相关症状。结果在99例患者417例次的DPMAS治疗过程中,8例患者发生13例次(3.1%)VVR;在DPMAS治疗前,VVR组SBP、心率和静脉压分别为(105.7±8.7) mmHg、(71.3±11.2) bpm和(3.5±7.3)mmHg,均显著低于或慢于非VVR组【分别为(114.6±14.7) mmHg、(82.7±15.0)bpm和(14.7±16.5)mmHg,P＜0.05】,而两组在舒张压、平均动脉压、动脉压和跨膜压方面,无显著性差异(P>0.05);在DPMAS治疗前SBP≤110 mmHg人群,VVR发生率为5.7%,占发生VVR例次的76.9%,在SBP＞110 mmHg人群,VVR发生率为1.2%,占发生VVR例次的23.1%;在所有发生VVR的患者,停止分浆泵,给予羟乙基淀粉氯化钠注射液500 ml静脉滴注,均改善症状;对于SBP偏低(≤110mmHg)的患者,治疗前预防性给予羟乙基淀粉氯化钠注射液静脉滴注能有效降低VVR发生率。结论 DPMAS治疗相关VVR是一种较为少见的并发症。治疗前SBP偏低是影响VVR发生的重要因素,给予羟乙基淀粉氯化钠注射液是预防VVR发生的主要措施。

关键词: 肝衰竭, 双重血浆分子吸附系统, 血管迷走神经反应, 治疗

Abstract: Objective The aim of this study was to investigate vasovagal reaction (VVR) in patients with liver failure (LF) during double plasma molecular adsorption system (DPMAS) treatment. Methods 82 patients with LF and 17 patients with pre-LF were encountered in our hospital between January 2021 and March 2022, and all underwent DPMAS treatment. The VVR was defined as decreased blood pressure and slowed heart beats with concomitant symptoms. Results Out of the 99 patients with LF or pre-LF, the incidence of VVR was 3.1% in 417 times of DPMAS from 8 patients; before the DPMAS treatment, the systolic blood pressure, heart beats and venous pressure in patients with VVR were (105.7±8.7) mmHg, (71.3±11.2) bpm and (3.5±7.3)mmHg, all significantly lower or slower than [(114.6±14.7) mmHg, (82.7±15.0)bpm and (14.7±16.5)mmHg, respectively, P＜0.05] in patients without VVR, while there were no significant differences as respect to the diastolic pressure, mean arterial pressure, arterial pressure and transmembrane pressure between the two groups(P>0.05); the incidence of VVR was 5.7% in patients with SBP≤110 mmHg before DPMAS, accounting for 76.9% of all, while the VVR was 1.2% in patients with SBP＞110 mmHg, accounting for 23.1% of all; in all patients with VVR, the DPMAS was discontinued, administered with hydroxyethyl starch sodium chloride intravenously, and all recovered; the prophylactic infusion of hydroxyethyl starch sodium chloride intravenously in patients with SBP≤110 mmHg before DPMAS decreased the incidence of VVR. Conclusions The DPMAS treatment-related VVR is a relatively rare complication, and the decreased SBP and slow HR before treatment are the important factors impacting the occurrence of VVR. The intravenous infusion of hydroxyethyl starch sodium chloride is the main measure to prevent the occurrence of VVR.

Key words: Liver failure, Double plasma molecular adsorption system, Vasovagal reaction, Therapy

贺锦帆, 姚佳, 赵强, 王娟, 白津佳, 赵凝慧. 双重血浆分子吸附系统治疗肝衰竭患者发生血管迷走神经反应相关因素分析及其处理对策研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 828-831.

He Jinfan, Yao Jia, Zhao Qiang, et al.. Vasovagal reaction in patients with liver failure during double plasma molecular adsorption system treatment[J]. Journal of Practical Hepatology, 2022, 25(6): 828-831.

参考文献

[1] 中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2018 年版).实用肝脏病杂志,2019,22(2):164-171.
[2] 中华医学会肝病学分会重型肝病与人工肝学组,白浪,陈煜,等.人工肝血液净化技术临床应用专家共识(2022年版).实用肝脏病杂志,2022,25(3):457-468.
[3] Yao J, Li S, Zhou L, et al. Therapeutic effect of double plasma molecular adsorption system and sequential half-dose plasma exchange in patients with HBV-related acute-on-chronic liver failure. J Clin Apher, 2019,34(4):392-398.
[4] Rama B N, Mohiuddin S M, Mooss A N, et al. Double-blind, randomized, placebo-controlled evaluation of atropine to prevent vasovagal reaction during removal of femoral arterial sheaths. Pharmacotherapy, 1997,17(5):867-873.
[5] Yang Y, Zhang Z, Li T, et al. Risk factors for vasovagal reaction associated with cerebral angiography via femoral catheterisation. Interv Neuroradiol, 2017,23(5):546-550.
[6] van Lieshout J J, Wieling W, Karemaker J M, et al. The vasovagal response. Clin Sci (Lond), 1991,81(5):575-586.
[7] Ma S, Xie Z, Zhang H, et al. Characterization of an artificial liver support system-related vasovagal reaction. Biomed Res Int, 2020,2020:6313480.
[8] Zervou E K, Ziciadis K, Karabini F, et al. Vasovagal reactions in blood donors during or immediately after blood donation. Transfus Med, 2005,15(5):389-394.
[9] Kennedy D J, Schneider B, Smuck M, et al. The use of moderate sedation for the secondary prevention of adverse vasovagal reactions. Pain Med, 2015,16(4):673-679.
[10] Minkis K, Whittington A, Alam M. Dermatologic surgery emergencies: Complications caused by occlusion and blood pressure. J Am Acad Dermatol, 2016,75(2):243-262.
[11] Kiat A C, Leung D Y, Lo S, et al. Effect of local anesthesia and intravenous sedation on pain perception and vasovagal reactions during femoral arterial sheath removal after percutaneous coronary intervention. Int J Cardiol, 2007,116(3):321-326.
[12] Pavlin D J, Links S, Rapp S E, et al. Vaso-vagal reactions in an ambulatory surgery center. Anesth Analg, 1993,76(5):931-935.
[13] Wu W J, Goldberg L H, Rubenzik M K, et al. Review of the evaluation and treatment of vasovagal reactions in outpatient procedures. Dermatol Surg, 2018,44(12):1483-1488.
[14] Alboni P. The different clinical presentations of vasovagal syncope. Heart, 2015,101(9):674-678.
[15] Benditt D G, Chen M Y, Hansen R, et al. Characterization of subcutaneous microvascular blood flow during tilt table-induced neurally mediated syncope. J Am Coll Cardiol, 1995,25(1):70-75.
[16] Graham D T, Kabler J D, Lunsford L J. Vasovagal fainting: a diphasic response. Psychosom Med, 1961,23:493-507.
[17] Gillet P, Rapaille A, Benoit A, et al. First-time whole blood donation: a critical step for donor safety and retention on first three donations. Transfus Clin Biol, 2015,22(5-6):312-317.
[18] Romme J J, van Dijk N, Boer K R, et al. Influence of age and gender on the occurrence and presentation of reflex syncope. Clin Auton Res, 2008,18(3):127-133.
[19] Narbey D, Fillet A M, Jbilou S, et al. Case-control study of immediate and delayed vasovagal reactions in blood donors. Vox Sang, 2016,111(3):257-265.
[20] France C R, France J L, Frame-Brown T A, et al. Fear of blood draw and total draw time combine to predict vasovagal reactions among whole blood donors. Transfusion, 2016,56(1):179-185.

双重血浆分子吸附系统治疗肝衰竭患者发生血管迷走神经反应相关因素分析及其处理对策研究^*

Vasovagal reaction in patients with liver failure during double plasma molecular adsorption system treatment

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	韩芳, 李佳峥, 南月敏. 肝硬化并发急性肾损伤诊治进展[J]. 实用肝脏病杂志, 2022, 25(6): 768-771.
[2]	李向阳, 丁光伟, 靳铭. 恩替卡韦治疗慢性乙型肝炎合并NAFLD患者临床疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 776-779.
[3]	吴凤萍, 崔丹丹, 王怡恺, 李梅, 刘晨瑞, 南希, 贾晓黎, 党双锁. 血清BAFF预测聚乙二醇干扰素-α治疗非活动性HBsAg携带者临床治愈的效能分析^*[J]. 实用肝脏病杂志, 2022, 25(6): 780-783.
[4]	许海玲, 秦刚, 薛红, 章颖. 艾尔巴韦/格拉瑞韦治疗基因1b型慢性丙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 788-791.
[5]	赵资德, 吴令杰, 张海生, 陈瑞烈. 纠正低蛋白血症减少抗结核药物性肝损伤发生临床研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 792-795.
[6]	孙峥, 王笑烨, 袁景, 梁丽. 达格列净联合利拉鲁肽治疗非酒精性脂肪性肝病合并2型糖尿病患者短期疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 796-799.
[7]	孙凌, 杭玮, 邓国忠. 二甲双胍联合吡格列酮治疗非酒精性脂肪性肝病合并2型糖尿病患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 804-807.
[8]	李荣, 曹晶晶, 李晶, 潘峰. 慢加急性/亚急性乙型肝炎肝衰竭患者发病诱因及影响临床转归因素分析^*[J]. 实用肝脏病杂志, 2022, 25(6): 832-835.
[9]	孙静, 张伟伟, 马智勇, 代树本, 邓彦东. 经颈静脉肝内门体分流术联合胃冠状静脉栓塞术治疗乙型肝炎肝硬化并发食管胃静脉曲张患者效果分析^*[J]. 实用肝脏病杂志, 2022, 25(6): 853-856.
[10]	詹致远, 申洋, 王凡冰. 内镜下套扎术联合奥美拉唑和奥曲肽治疗肝硬化并发食管静脉曲张首次出血患者短期疗效分析^*[J]. 实用肝脏病杂志, 2022, 25(6): 865-868.
[11]	毛月琴, 张红侠, 宋海燕, 刘波, 董静, 陈照林, 杨小康, 周旭, 娄方明. TACE联合毒痰瘀脾虚方治疗原发性肝癌患者临床疗效研究[J]. 实用肝脏病杂志, 2022, 25(6): 873-876.
[12]	蓝思荣, 徐继威, 张耀明, 李雄, 沈登文, 苏鸿辉. 实时超声造影与3D超声融合成像导航评估微波消融治疗原发性肝癌患者价值研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 889-892.
[13]	蒋彪, 付彤, 吴旭栋. 高强度聚焦超声联合人工液胸治疗不可切除小儿肝母细胞瘤短期疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 893-896.
[14]	陆晓明, 陈学敏. PTBD联合二期PTCSL术治疗急性胆管炎伴胆总管结石患者疗效及安全性评价^*[J]. 实用肝脏病杂志, 2022, 25(6): 901-904.
[15]	沈一芃, 祝峻峰. 肝硬化并发自发性细菌性腹膜炎临床研究进展^*[J]. 实用肝脏病杂志, 2022, 25(6): 909-912.